Patients could be reverted to their previous injectable SRL if IGF-I was ≥ 1.3 × ULN for 2 consecutive visits while on the highest dose of OOC (80 mg/day) or placebo accompanied by worsening clinical signs or symptoms of acromegaly. This evidence concerns the gene IGF1 and acromegaly.